ranibizumab

Pfenex Inc (NYSE: PFNX) shares gained more than 20 percent after the company disclosed its macular degeneration drug candidate will get collaborative support from Hospira, Inc. (NYSE: HSP). San Diego-based Pfenex changed hands recently at $8.25, up $1.35. The drug under development is aimed at...